ArticleBlood advances2026

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Constantine S Tam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.